CrystalGenomics "Camrelizumab Combination Lowers Risk of Disease Progression and Death in Phase 3"

Reduces Disease Progression Risk by 63% and Mortality Risk by 45%

CrystalGenomics announced on the 21st that the Phase 3 clinical trial results of the combination therapy with 'Camrelizumab' for non-small cell lung cancer, for which it holds the rights, reduced the risk of disease progression and death.

CrystalGenomics logo. [Image provided by CrystalGenomics]

According to its partner, Hansoh Pharmaceutical, the Phase 3 clinical trial of Camrelizumab combined with chemotherapy (carboplatin, paclitaxel) in patients with non-small cell lung cancer showed a median progression-free survival (mPFS) of 8.5 months compared to 4.9 months in the control group receiving chemotherapy (carboplatin, paclitaxel). The hazard ratio (HR) for disease progression was statistically significantly reduced by 63% (HR=0.37). The hazard ratio for death (HR=0.55) was lowered by 45%.

In particular, the duration of response (DOR) for the Camrelizumab combination therapy, which measures the duration of tumor response (CR, PR), exceeded one year. CrystalGenomics explained that this indicates that once patients respond to Camrelizumab, the drug's efficacy can last longer. Additionally, they noted the confirmation of the 'long-tail effect,' a phenomenon characteristic of immuno-oncology drugs where symptoms do not worsen after administration and long-term survival is observed.

The study results were published in the Journal of Thoracic Oncology (JTO), an international academic journal in the field of lung cancer.

A CrystalGenomics official stated, "Camrelizumab has received approval from the Ministry of Food and Drug Safety for the final stage of clinical trial planning (bridging clinical trial) for marketing purposes targeting non-small cell lung cancer," adding, "Patient administration will begin in July."

Camrelizumab recorded sales of $1.7 billion (approximately KRW 2.25 trillion) last year. The company forecasts sales to reach $2.793 billion (approximately KRW 3.7 trillion) by 2026.